Analysts have given IQVIA Hldgs a total of 7 ratings, with the consensus rating being Neutral. The average one-year price target is $174.0, indicating a potential 8.32% upside.

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

The global Healthcare BPO Market, valued at US$337.6 billion in 2024 stood at US$417.7 billion in 2025 and is projected to advance at a resilient ...

The global Healthcare BPO Market, valued at US$337.6 billion in 2024 stood at US$417.7 billion in 2025 and is projected to ...

USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- As artificial intelligence reshapes the future of medicine, understanding ...

It's a strategic and scalable approach to one of the biggest gaps in modern healthcare: detecting chronic conditions like diabetic retinopathy before symptoms appear. Avant and Ainnova are now proving ...

However, thanks to the ultra-compact, high-resolution spectrometer developed by KAIST researchers, it is now expected that light's color information can be utilized even within smartphones or ...

Combining IQVIA Holdings' Debt And Its 23% Return On Equity IQVIA Holdings does use a high amount of debt to increase returns. It has a debt to equity ratio of 2.31. There's no doubt its ROE is decent ...